This report was recently updated on November 16 2024 with the latest and most recent
market numbers
Global Pulmonary Arterial Hypertension Market Size, Trends & Analysis - Forecasts to 2027 By Drug Class (Endothelin Receptor Antagonists (ERAs), PDE - 5 Inhibitors, Prostacyclin & Prostacyclin Analogs, SGC Stimulators), By Type (Branded, Generics), By Route of Administration (Oral, Intravenous/Subcutaneous, Inhalational), By Region (North America, Asia Pacific, Central & South America, Europe, and the Middle East & Africa), End-User Landscape Analysis, Company Market Share Analysis, and Competitor Analysis
The Global Pulmonary Arterial Hypertension Market is projected to grow at a CAGR value of 5.2% from 2022 to 2027.
Pulmonary hypertension is not rare and is estimated to afflict about 1% of the world's population. The prevalence of pulmonary hypertension is estimated to be around 10% in people over 65. According to United Therapeutics, roughly 45,000 people in the United States have pulmonary arterial hypertension.
Some of the factors driving market expansion include an increase in the prevalence of pulmonary arterial hypertension, a comprehensive product pipeline, excessive government interventions, and an increasing worldwide aging population.
Changing lifestyle habits such as reduced physical activity, smoking, and alcohol intake, an increase in patients with cardiac disease, an uptick in conditions such as asthma, and an increase in health sensitivity and consciousness contribute to market growth.
Additionally, increased research and development investments in the healthcare industry around the world and an increase in generic medicine innovation in emerging economies are promoting the overall market growth.
As per the American Lung Association, left heart disease, which affects about 1.3 million people, is one of the most common causes of pulmonary hypertension. Around 50% of people with left heart disease cultivate pulmonary hypertension, which occurs in 10% of cases as a combination of post- and precapillary hypertension.
The dysregulated proliferation of vascular and tumor cells, and sparked interest in repurposing oncology medications fuels pulmonary arterial hypertension research and diagnostics even more.
Annually, 3–10 new instances of pulmonary arterial hypertension are diagnosed per million persons. Pseudoarterial hypertension is becoming more common due to developments in pathobiology and the increased use of certain medicines or illegal substances.
Congenital heart diseases and other ailments such as HIV infection, chronic liver disease (cirrhosis), and connective tissue disorders (scleroderma, lupus, and others) are fueling market expansion.
Also, the market growth includes the increased prevalence of obstructive sleep apnea, the rapidly increasing prevalence of chronic obstructive pulmonary disease (COPD) among the elderly, and alterations in a gene passed down via generations (heritable pulmonary arterial hypertension).
COVID-19 has had a minor impact on the pulmonary arterial hypertension market, and the lingering consequences of the coronavirus pandemic may persist in the coming years. The industry's response to the coronavirus outbreak peaked in early 2020 when pulmonary arterial hypertension patients were at a greater risk of acquiring the virus.
According to a survey conducted in the United States by 77 Comprehensive Care Centers for Pulmonary Hypertension (PH), the occurrence of coronavirus disease among patients with pulmonary arterial hypertension (PAH) was 2.1 cases per 1,000 patients, and the affiliated mortality rate was 12 percent, which is similar to the general United States population.
Other obstacles to the industry's growth included delays in diagnostic testing, revised hospitalization, emergency treatment protocols, and a disrupted pharmaceutical supply chain.
The Russian invasion of Ukraine could cause long-term supply chain disruptions that might impact the healthcare industry in the future. Disruptions such as shuttered aviation, expensive energy, the influence on the raw material extraction for medical supplies, worldwide reliance on oil and gas, and the threat of cyber-attacks owing to the ongoing conflict are to be expected in the healthcare industry.
Furthermore, like many others, the healthcare industry is susceptible because it relies on oil production, natural gas, and other metals to manufacture supplies and equipment. The region is home to aluminum, nickel, chromium, halogen gas, and steel, utilized in surgical tools, orthopedic devices, and medical equipment.
Prostacyclin and prostacyclin analogs are the most prominent pulmonary arterial hypertension market segment from 2022 to 2027. IV epoprostenol therapy improves cardiovascular variables, considerably reduces symptoms of breathlessness and tiredness, and boosts exercise tolerance in individuals with PAH, according to clinical research (6MWD). Additional benefits include decreased total pulmonary resistance, pulmonary vascular resistance (PVR), mPAP, and increased cardiac index and stroke volume.
On the other hand, the SGC simulators are expected to be the fastest-growing segment in the market. The stimulation of SGC aids in the mediation of physiological responses such as vascular smooth muscle, inflammatory suppression, and thromboembolism propelling segment growth.
Generic is the most prominent pulmonary arterial hypertension market segment from 2022 to 2027. The major benefit of generic medications is the lower cost, up to 85% cheaper than a brand-name drug. Lower-cost generic pharmaceuticals have been shown to improve the patient's healthcare outcomes by increasing the likelihood that they will take important prescribed medication by their doctors.
Branded is expected to be the fastest-growing segment in the market. According to studies, there are no substantial differences between brand-name and generic medications. However, it is critical for some medications to prefer branded drugs, such as modified release theophylline, modified release diltiazem, and modified release anti-epileptic therapies. As the drug's bioavailability differs amongst preparations, driving the segment growth.
Oral is the most prominent pulmonary arterial hypertension market segment from 2022 to 2027. The most common method of medicine delivery is through the oral route. It is the recommended route for its benefits, such as non-invasiveness, patient compliance, and ease of medication delivery. Drug solubility, mucosal transparency, and digestive tract environment stabilization are all factors that influence oral drug absorption.
Since inhaled medications are targeted to the specific receptor, they can be delivered at a smaller concentration than systemic treatments (oral or injectable), resulting in fewer milder side effects. Clinically, the three types of aerosol devices (MDI, DPI, and nebulizer) may be equal. Thereby, the market for the inhalational route of administration is expected to be the fastest-growing segment in the market.
North America (the United States, Canada, and Mexico) will dominate the pulmonary arterial hypertension market from 2022 to 2027. The sophisticated healthcare system in the region, which allows access to advanced treatments, is responsible for the huge share. Increased awareness, a high diagnosis rate, and supportive government measures contribute to the market's growth.
The United States is expected to have the lion's share in the North American pulmonary arterial hypertension market. This is attributed to the increased incidence of chronic and infectious diseases. A high diagnostic rate and growing investment for enhanced medical institutions in this region propel market growth.
Moreover, the Asia-Pacific region is expected to be the fastest-growing pulmonary arterial hypertension market segment during the forecast period. The expansion is supported by better healthcare infrastructure in developing countries, supportive government initiatives, and the rapidly expanding generic drugs market.
India is expected to hold the largest share in the Asia Pacific pulmonary arterial hypertension market. With a wide population base, an expanding incidence of diseases such as HIV increased collaboration for novel product innovation, and a spike in the proportion of patients with cardiogenic shock, the Indian pulmonary arterial hypertension market is expected to propel during the forecast period.
United Therapeutics Corporation, Bayer, Gilead Sciences, Inc., Johnson & Johnson, Viatris Inc., GlaxoSmithKline, Sandoz Inc. (Novartis), Lupin Pharmaceuticals, Inc., Sun Pharmaceutical Industries, Inc., and Teva Pharmaceutical Industries Ltd, among others, are the key players in the pulmonary arterial hypertension market.
Please note: This is not an exhaustive list of companies profiled in the report.
The global pulmonary arterial hypertension market has observed several strategic alliances between key players to launch new products with added functionalities and maintain revenue share & profitability. Organic and inorganic growth strategies adopted by small players have been the highlight of this market.
Chapter 1 Research Methodology
1.1 Research Assumptions
1.2 Research Methodology
1.2.1 Estimates and Forecast Timeline
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 GME’s Internal Database
1.3.3 Primary Research
1.3.4 Secondary Sources & Third-Party Perspectives
1.3.4.1 Company Information Sources: Annual Reports, Investor Presentation, Press Release, SEC Filing, Company Blogs & Website
1.3.4.2 Secondary Data Sources: World Health Organization (WHO), American Lung Association PAH, Medline and Embase databases, European Society of Cardiology (ESC)/European Respiratory Society (ERS) guidelines
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Data Visualization
1.6 Data Validation & Publishing
1.7 Market Model
1.7.1 Model Details
1.7.1.1 Top-Down Approach
1.7.1.2 Bottom-Up Approach
1.8 Market Segmentation & Scope
1.9 Market Definition
Chapter 2 Executive Summary
2.1. Global Market Outlook
2.2 Drug Class Outlook
2.3 Route of Administration Outlook
2.4 Type Outlook
2.5 Regional Outlook
Chapter 3 Global Pulmonary Arterial Hypertension Market Trend Analysis
3.1. Market Introduction
3.2 Penetration & Growth Prospect Mapping
3.3 Impact of COVID-19 on the Pulmonary Arterial Hypertension Market
3.4 Metric Data on Pulmonary Arterial Hypertension Industry
3.5 Market Driver Analysis
3.5.1 Market Driver Analysis
3.5.2 Market Restraint Analysis
3.5.3 Industry Challenges
3.5.4 Industry Opportunities
3.6 Porter’s Five Analysis
3.6.1 Supplier Power
3.6.2 Buyer Power
3.6.3 Substitution Threat
3.6.4 Threat from New Entrant
3.7 Market Entry Strategies
Chapter 4 Pulmonary Arterial Hypertension Market: Drug Class Trend Analysis
4.1 Drug Class: Historic Data vs. Forecast Data Analysis, 2021 vs. 2027
4.2 Endothelin Receptor Antagonists (ERAs)
4.2.1 Market Estimates & Forecast Analysis of Endothelin Receptor Antagonists (ERAs) Segment, By Region, 2019-2027 (USD Billion)
4.3 PDE - 5 Inhibitors
4.3.1 Market Estimates & Forecast Analysis of PDE - 5 Inhibitors Segment, By Region, 2019-2027 (USD Billion)
4.4 Prostacyclin and Prostacyclin Analogs
4.4.1 Market Estimates & Forecast Analysis of PDE - 5 Prostacyclin and Prostacyclin Analogs Segment, By Region, 2019-2027 (USD Billion)
4.5 SGC Stimulators
4.5.1 Market Estimates & Forecast Analysis of PDE - 5 SGC Stimulators Segment, By Region, 2019-2027 (USD Billion)
Chapter 5 Pulmonary Arterial Hypertension Market: Route of Administration Trend Analysis
5.1 Route of Administration: Historic Data vs. Forecast Data Analysis, 2021 vs. 2027
5.2 Oral
5.2.1 Market Estimates & Forecast Analysis of Oral Segment, By Region, 2019-2027 (USD Billion)
5.3 Intravenous/ Subcutaneous
5.3.1 Market Estimates & Forecast Analysis of Intravenous/ Subcutaneous Segment, By Region, 2019-2027 (USD Billion)
5.4 Inhalational
5.4.1 Market Estimates & Forecast Analysis of Inhalational Segment, By Region, 2019-2027 (USD Billion)
Chapter 6 Pulmonary Arterial Hypertension Market: Type Trend Analysis
6.1 Type: Historic Data vs. Forecast Data Analysis, 2021 vs. 2027
6.2 Branded
6.2.1 Market Estimates & Forecast Analysis of Branded Segment, By Region, 2019-2027 (USD Billion)
6.3 Generics
6.3.1 Market Estimates & Forecast Analysis of Generics Segment, By Region, 2019-2027 (USD Billion)
Chapter 7 Pulmonary Arterial Hypertension Market, By Region
7.1 Regional Outlook
7.2 North America
7.2.1 Market Estimates & Forecast Analysis, By Country 2019-2027 (USD Billion)
7.2.2 Market Estimates & Forecast Analysis, By Drug Class, 2019-2027 (USD Billion)
7.2.3 Market Estimates & Forecast Analysis, By Route of Administration, 2019-2027 (USD Billion)
7.2.4 Market Estimates & Forecast Analysis, By Type, 2019-2027 (USD Billion)
7.2.5 U.S.
7.2.5.1 Market Estimates & Forecast Analysis, By Drug Class, 2019-2027 (USD Billion)
7.2.5.2 Market Estimates & Forecast Analysis, By Route of Administration, 2019-2027 (USD Billion)
7.2.5.3 Market Estimates & Forecast Analysis, By Type, 2019-2027 (USD Billion)
7.2.6 Canada
7.2.6.1 Market Estimates & Forecast Analysis, By Drug Class, 2019-2027 (USD Billion)
7.2.6.2 Market Estimates & Forecast Analysis, By Route of Administration, 2019-2027 (USD Billion)
7.2.6.3 Market Estimates & Forecast Analysis, By Type, 2019-2027 (USD Billion)
7.5.7 Mexico
7.5.5.1 Market Estimates & Forecast Analysis, By Drug Class, 2019-2027 (USD Billion)
7.5.5.2 Market Estimates & Forecast Analysis, By Route of Administration, 2019-2027 (USD Billion)
7.5.5.3 Market Estimates & Forecast Analysis, By Type, 2019-2027 (USD Billion)
7.3 Europe
7.3.1 Market Estimates & Forecast Analysis, By Country 2019-2027 (USD Billion)
7.3.2 Market Estimates & Forecast Analysis, By Drug Class, 2019-2027 (USD Billion)
7.3.3 Market Estimates & Forecast Analysis, By Route of Administration, 2019-2027 (USD Billion)
7.3.4 Market Estimates & Forecast Analysis, By Type, 2019-2027 (USD Billion)
7.3.5 Germany
7.3.5.1 Market Estimates & Forecast Analysis, By Drug Class, 2019-2027 (USD Billion)
7.3.5.2 Market Estimates & Forecast Analysis, By Route of Administration, 2019-2027 (USD Billion)
7.3.5.3 Market Estimates & Forecast Analysis, By Type, 2019-2027 (USD Billion)
7.3.6 UK
7.3.6.1 Market Estimates & Forecast Analysis, By Drug Class, 2019-2027 (USD Billion)
7.3.6.2 Market Estimates & Forecast Analysis, By Route of Administration, 2019-2027 (USD Billion)
7.3.6.3 Market Estimates & Forecast Analysis, By Type, 2019-2027 (USD Billion)
7.3.7 France
7.3.7.1 Market Estimates & Forecast Analysis, By Drug Class, 2019-2027 (USD Billion)
7.3.7.2 Market Estimates & Forecast Analysis, By Route of Administration, 2019-2027 (USD Billion)
7.3.7.3 Market Estimates & Forecast Analysis, By Type, 2019-2027 (USD Billion)
7.3.8 Russia
7.3.8.1 Market Estimates & Forecast Analysis, By Drug Class, 2019-2027 (USD Billion)
7.3.8.2 Market Estimates & Forecast Analysis, By Route of Administration, 2019-2027 (USD Billion)
7.3.8.3 Market Estimates & Forecast Analysis, By Type, 2019-2027 (USD Billion)
7.3.9 Italy
7.3.9.1 Market Estimates & Forecast Analysis, By Drug Class, 2019-2027 (USD Billion)
7.3.9.2 Market Estimates & Forecast Analysis, By Route of Administration, 2019-2027 (USD Billion)
7.3.9.3 Market Estimates & Forecast Analysis, By Type, 2019-2027 (USD Billion)
7.3.10 Spain
7.3.10.1 Market Estimates & Forecast Analysis, By Drug Class, 2019-2027 (USD Billion)
7.3.10.2 Market Estimates & Forecast Analysis, By Route of Administration, 2019-2027 (USD Billion)
7.3.10.3 Market Estimates & Forecast Analysis, By Type, 2019-2027 (USD Billion)
7.3.11 Rest of Europe
7.3.11.1 Market Estimates & Forecast Analysis, By Drug Class, 2019-2027 (USD Billion)
7.3.11.2 Market Estimates & Forecast Analysis, By Route of Administration, 2019-2027 (USD Billion)
7.3.11.3 Market Estimates & Forecast Analysis, By Type, 2019-2027 (USD Billion)
7.4 Asia Pacific
7.4.1 Market Estimates & Forecast Analysis, By Country 2019-2027 (USD Billion)
7.4.2 Market Estimates & Forecast Analysis, By Drug Class, 2019-2027 (USD Billion)
7.4.3 Market Estimates & Forecast Analysis, By Route of Administration, 2019-2027 (USD Billion)
7.4.4 Market Estimates & Forecast Analysis, By Type, 2019-2027 (USD Billion)
7.4.5 China
7.4.5.1 Market Estimates & Forecast Analysis, By Drug Class, 2019-2027 (USD Billion)
7.4.5.2 Market Estimates & Forecast Analysis, By Route of Administration, 2019-2027 (USD Billion)
7.4.5.3 Market Estimates & Forecast Analysis, By Type, 2019-2027 (USD Billion)
7.4.6 India
7.4.6.1 Market Estimates & Forecast Analysis, By Drug Class, 2019-2027 (USD Billion)
7.4.6.2 Market Estimates & Forecast Analysis, By Route of Administration, 2019-2027 (USD Billion)
7.4.6.3 Market Estimates & Forecast Analysis, By Type, 2019-2027 (USD Billion)
7.4.7 Japan
7.4.7.1 Market Estimates & Forecast Analysis, By Drug Class, 2019-2027 (USD Billion)
7.4.7.2 Market Estimates & Forecast Analysis, By Route of Administration, 2019-2027 (USD Billion)
7.4.7.3 Market Estimates & Forecast Analysis, By Type, 2019-2027 (USD Billion)
7.4.8 Australia
7.4.8.1 Market Estimates & Forecast Analysis, By Drug Class, 2019-2027 (USD Billion)
7.4.8.2 Market Estimates & Forecast Analysis, By Route of Administration, 2019-2027 (USD Billion)
7.4.8.3 Market Estimates & Forecast Analysis, By Type, 2019-2027 (USD Billion)
7.4.9 South Korea
7.4.9.1 Market Estimates & Forecast Analysis, By Drug Class, 2019-2027 (USD Billion)
7.4.9.2 Market Estimates & Forecast Analysis, By Route of Administration, 2019-2027 (USD Billion)
7.4.9.3 Market Estimates & Forecast Analysis, By Type, 2019-2027 (USD Billion)
7.3.10 Rest of Asia Pacific
7.3.10.1 Market Estimates & Forecast Analysis, By Drug Class, 2019-2027 (USD Billion)
7.3.10.2 Market Estimates & Forecast Analysis, By Route of Administration, 2019-2027 (USD Billion)
7.3.10.3 Market Estimates & Forecast Analysis, By Type, 2019-2027 (USD Billion)
7.5 Central & South America
7.5.1 Market Estimates & Forecast Analysis, By Country 2019-2027 (USD Billion)
7.5.2 Market Estimates & Forecast Analysis, By Drug Class, 2019-2027 (USD Billion)
7.5.3 Market Estimates & Forecast Analysis, By Route of Administration, 2019-2027 (USD Billion)
7.5.4 Market Estimates & Forecast Analysis, By Type, 2019-2027 (USD Billion)
7.5.5 Brazil
7.5.5.1 Market Estimates & Forecast Analysis, By Drug Class, 2019-2027 (USD Billion)
7.5.5.2 Market Estimates & Forecast Analysis, By Route of Administration, 2019-2027 (USD Billion)
7.5.5.3 Market Estimates & Forecast Analysis, By Type, 2019-2027 (USD Billion)
7.5.6 Rest of Central & South America
7.5.6.1 Market Estimates & Forecast Analysis, By Drug Class, 2019-2027 (USD Billion)
7.5.6.2 Market Estimates & Forecast Analysis, By Route of Administration, 2019-2027 (USD Billion)
7.5.6.3 Market Estimates & Forecast Analysis, By Type, 2019-2027 (USD Billion)
7.6 Middle East & Africa
7.6.1 Market Estimates & Forecast Analysis, By Country 2019-2027 (USD Billion)
7.6.2 Market Estimates & Forecast Analysis, By Drug Class, 2019-2027 (USD Billion)
7.6.3 Market Estimates & Forecast Analysis, By Route of Administration, 2019-2027 (USD Billion)
7.6.4 Market Estimates & Forecast Analysis, By Type, 2019-2027 (USD Billion)
7.6.5 Saudi Arabia
7.6.5.1 Market Estimates & Forecast Analysis, By Drug Class, 2019-2027 (USD Billion)
7.6.5.2 Market Estimates & Forecast Analysis, By Route of Administration, 2019-2027 (USD Billion)
7.6.5.3 Market Estimates & Forecast Analysis, By Type, 2019-2027 (USD Billion)
7.6.6 United Arab Emirates
7.6.6.1 Market Estimates & Forecast Analysis, By Drug Class, 2019-2027 (USD Billion)
7.6.6.2 Market Estimates & Forecast Analysis, By Route of Administration, 2019-2027 (USD Billion)
7.6.6.3 Market Estimates & Forecast Analysis, By Type, 2019-2027 (USD Billion)
7.6.7 South Africa
7.6.7.1 Market Estimates & Forecast Analysis, By Drug Class, 2019-2027 (USD Billion)
7.6.7.2 Market Estimates & Forecast Analysis, By Route of Administration, 2019-2027 (USD Billion)
7.6.7.3 Market Estimates & Forecast Analysis, By Type, 2019-2027 (USD Billion)
7.5.8 Rest of Middle East & Africa
7.5.8.1 Market Estimates & Forecast Analysis, By Drug Class, 2019-2027 (USD Billion)
7.5.8.2 Market Estimates & Forecast Analysis, By Route of Administration, 2019-2027 (USD Billion)
7.5.8.3 Market Estimates & Forecast Analysis, By Type, 2019-2027 (USD Billion)
Chapter 8 Competitive Analysis
8.1 Key Global Players, Recent Developments & their Impact on the Industry
8.2 Four Quadrant Competitor Positioning Matrix
8.2.1 Key Innovators
8.2.2 Market Leaders
8.2.3 Emerging Players
8.2.4 Market Challengers
8.3 Vendor Landscape Analysis
8.4 End-User Landscape Analysis
8.5 Company Market Share Analysis, 2021
Chapter 9 Company Profile Analysis
9.1 United Therapeutics Corporation
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Strategic Initiatives
9.1.4 Product Benchmarking
9.2 Baye
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Strategic Initiatives
9.2.4 Product Benchmarking
9.3 Gilead Sciences, Inc
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Strategic Initiatives
9.3.4 Product Benchmarking
9.4 Johnson & Johnson
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Strategic Initiatives
9.4.4 Product Benchmarking
9.5 Viatris Inc.
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Strategic Initiatives
9.5.4 Product Benchmarking
9.6 GlaxoSmithKline
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Strategic Initiatives
9.6.4 Product Benchmarking
9.7 Sandoz Inc. (Novartis)
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Strategic Initiatives
9.7.4 Product Benchmarking
9.8 Lupin Pharmaceuticals, Inc
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Strategic Initiatives
9.8.4 Product Benchmarking
9.9 Sun Pharmaceutical Industries, Inc.
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Strategic Initiatives
9.9.4 Product Benchmarking
9.10 Other Companies
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Strategic Initiatives
9.10.4 Product Benchmarking
List of Tables
1 Technological Advancements In Pulmonary Arterial Hypertension Market
2 Global Pulmonary Arterial Hypertension Market: Key Market Drivers
3 Global Pulmonary Arterial Hypertension Market: Key Market Challenges
4 Global Pulmonary Arterial Hypertension Market: Key Market Opportunities
5 Global Pulmonary Arterial Hypertension Market: Key Market Restraints
6 Global Pulmonary Arterial Hypertension Market Estimates & Forecast Analysis, 2019-2027 (USD Billion)
7 Global Pulmonary Arterial Hypertension Market, By Drug Class, 2019-2027 (USD Billion)
8 Endothelin Receptor Antagonists (ERAs): Global Pulmonary Arterial Hypertension Market, By Region, 2019-2027 (USD Billion)
9 PDE - 5 Inhibitors: Global Pulmonary Arterial Hypertension Market, By Region, 2019-2027 (USD Billion)
10 Prostacyclin and Prostacyclin Analogs: Global Pulmonary Arterial Hypertension Market, By Region, 2019-2027 (USD Billion)
11 SGC Stimulators: Global Pulmonary Arterial Hypertension Market, By Region, 2019-2027 (USD Billion)
12 Global Pulmonary Arterial Hypertension Market, By Route of Administration, 2019-2027 (USD Billion)
13 Oral: Global Pulmonary Arterial Hypertension Market, By Region, 2019-2027 (USD Billion)
14 Intravenous/ Subcutaneous: Global Pulmonary Arterial Hypertension Market, By Region, 2019-2027 (USD Billion)
15 Inhalational: Global Pulmonary Arterial Hypertension Market, By Region, 2019-2027 (USD Billion)
16 Global Pulmonary Arterial Hypertension Market, By Type, 2019-2027 (USD Billion)
17 Generics: Global Pulmonary Arterial Hypertension Market, By Region, 2019-2027 (USD Billion)
18 Branded: Global Pulmonary Arterial Hypertension Market, By Region, 2019-2027 (USD Billion)
19 Regional Analysis: Global Pulmonary Arterial Hypertension Market, By Region, 2019-2027 (USD Billion)
20 North America: Pulmonary Arterial Hypertension Market, By Drug Class, 2019-2027 (USD Billion)
21 North America: Pulmonary Arterial Hypertension Market, By Route of Administration, 2019-2027 (USD Billion)
22 North America: Pulmonary Arterial Hypertension Market, By Type , 2019-2027 (USD Billion)
23 North America: Pulmonary Arterial Hypertension Market, By Country, 2019-2027 (USD Billion)
24 U.S: Pulmonary Arterial Hypertension Market, By Drug Class, 2019-2027 (USD Billion)
25 U.S: Pulmonary Arterial Hypertension Market, By Route of Administration, 2019-2027 (USD Billion)
26 U.S: Pulmonary Arterial Hypertension Market, By Type, 2019-2027 (USD Billion)
27 Canada: Pulmonary Arterial Hypertension Market, By Drug Class, 2019-2027 (USD Billion)
28 Canada: Pulmonary Arterial Hypertension Market, By Route of Administration, 2019-2027 (USD Billion)
29 Canada: Pulmonary Arterial Hypertension Market, By Type, 2019-2027 (USD Billion)
30 Mexico: Pulmonary Arterial Hypertension Market, By Drug Class, 2019-2027 (USD Billion)
31 Mexico: Pulmonary Arterial Hypertension Market, By Route of Administration, 2019-2027 (USD Billion)
32 Mexico: Pulmonary Arterial Hypertension Market, By Type, 2019-2027 (USD Billion)
33 Europe: Pulmonary Arterial Hypertension Market, By Drug Class, 2019-2027 (USD Billion)
34 Europe: Pulmonary Arterial Hypertension Market, By Route of Administration, 2019-2027 (USD Billion)
35 Europe: Pulmonary Arterial Hypertension Market, By Type, 2019-2027 (USD Billion)
36 Europe: Pulmonary Arterial Hypertension Market, By Country, 2019-2027 (USD Billion)
37 Germany: Pulmonary Arterial Hypertension Market, By Drug Class, 2019-2027 (USD Billion)
38 Germany: Pulmonary Arterial Hypertension Market, By Route of Administration, 2019-2027 (USD Billion)
39 Germany: Pulmonary Arterial Hypertension Market, By Type, 2019-2027 (USD Billion)
40 UK: Pulmonary Arterial Hypertension Market, By Drug Class, 2019-2027 (USD Billion)
41 UK: Pulmonary Arterial Hypertension Market, By Route of Administration, 2019-2027 (USD Billion)
42 UK: Pulmonary Arterial Hypertension Market, By Type, 2019-2027 (USD Billion)
43 France: Pulmonary Arterial Hypertension Market, By Drug Class, 2019-2027 (USD Billion)
44 France: Pulmonary Arterial Hypertension Market, By Route of Administration, 2019-2027 (USD Billion)
45 France: Pulmonary Arterial Hypertension Market, By Type, 2019-2027 (USD Billion)
46 Italy: Pulmonary Arterial Hypertension Market, By Drug Class, 2019-2027 (USD Billion)
47 Italy: Pulmonary Arterial Hypertension Market, By T Route of Administration Ype, 2019-2027 (USD Billion)
48 Italy: Pulmonary Arterial Hypertension Market, By Type, 2019-2027 (USD Billion)
49 Spain: Pulmonary Arterial Hypertension Market, By Drug Class, 2019-2027 (USD Billion)
50 Spain: Pulmonary Arterial Hypertension Market, By Route of Administration, 2019-2027 (USD Billion)
51 Spain: Pulmonary Arterial Hypertension Market, By Type, 2019-2027 (USD Billion)
52 Rest Of Europe: Pulmonary Arterial Hypertension Market, By Drug Class, 2019-2027 (USD Billion)
53 Rest Of Europe: Pulmonary Arterial Hypertension Market, By Route of Administration, 2019-2027 (USD Billion)
54 Rest Of Europe: Pulmonary Arterial Hypertension Market, By Type, 2019-2027 (USD Billion)
55 Asia Pacific: Pulmonary Arterial Hypertension Market, By Drug Class, 2019-2027 (USD Billion)
56 Asia Pacific: Pulmonary Arterial Hypertension Market, By Route of Administration, 2019-2027 (USD Billion)
57 Asia Pacific: Pulmonary Arterial Hypertension Market, By Type, 2019-2027 (USD Billion)
58 Asia Pacific: Pulmonary Arterial Hypertension Market, By Country, 2019-2027 (USD Billion)
59 China: Pulmonary Arterial Hypertension Market, By Drug Class, 2019-2027 (USD Billion)
60 China: Pulmonary Arterial Hypertension Market, By Route of Administration, 2019-2027 (USD Billion)
61 China: Pulmonary Arterial Hypertension Market, By Type, 2019-2027 (USD Billion)
62 India: Pulmonary Arterial Hypertension Market, By Drug Class, 2019-2027 (USD Billion)
63 India: Pulmonary Arterial Hypertension Market, By Route of Administration, 2019-2027 (USD Billion)
64 India: Pulmonary Arterial Hypertension Market, By Type, 2019-2027 (USD Billion)
65 Japan: Pulmonary Arterial Hypertension Market, By Drug Class, 2019-2027 (USD Billion)
66 Japan: Pulmonary Arterial Hypertension Market, By Route of Administration, 2019-2027 (USD Billion)
67 Japan: Pulmonary Arterial Hypertension Market, By Type, 2019-2027 (USD Billion)
68 South Korea: Pulmonary Arterial Hypertension Market, By Drug Class, 2019-2027 (USD Billion)
69 South Korea: Pulmonary Arterial Hypertension Market, By Route of Administration, 2019-2027 (USD Billion)
70 South Korea: Pulmonary Arterial Hypertension Market, By Type, 2019-2027 (USD Billion)
71 Middle East & Africa: Pulmonary Arterial Hypertension Market, By Drug Class, 2019-2027 (USD Billion)
72 Middle East & Africa: Pulmonary Arterial Hypertension Market, By Route of Administration, 2019-2027 (USD Billion)
73 Middle East & Africa: Pulmonary Arterial Hypertension Market, By Type, 2019-2027 (USD Billion)
74 Middle East & Africa: Pulmonary Arterial Hypertension Market, By Country, 2019-2027 (USD Billion)
75 Saudi Arabia: Pulmonary Arterial Hypertension Market, By Drug Class, 2019-2027 (USD Billion)
76 Saudi Arabia: Pulmonary Arterial Hypertension Market, By Route of Administration, 2019-2027 (USD Billion)
77 Saudi Arabia: Pulmonary Arterial Hypertension Market, By Type, 2019-2027 (USD Billion)
78 UAE: Pulmonary Arterial Hypertension Market, By Drug Class, 2019-2027 (USD Billion)
79 UAE: Pulmonary Arterial Hypertension Market, By Route of Administration, 2019-2027 (USD Billion)
80 UAE: Pulmonary Arterial Hypertension Market, By Type, 2019-2027 (USD Billion)
81 Central & South America: Pulmonary Arterial Hypertension Market, By Drug Class, 2019-2027 (USD Billion)
82 Central & South America: Pulmonary Arterial Hypertension Market, By Route of Administration, 2019-2027 (USD Billion)
83 Central & South America: Pulmonary Arterial Hypertension Market, By Type, 2019-2027 (USD Billion)
84 Central & South America: Pulmonary Arterial Hypertension Market, By Country, 2019-2027 (USD Billion)
85 Brazil: Pulmonary Arterial Hypertension Market, By Drug Class, 2019-2027 (USD Billion)
86 Brazil: Pulmonary Arterial Hypertension Market, By Route of Administration, 2019-2027 (USD Billion)
87 Brazil: Pulmonary Arterial Hypertension Market, By Type, 2019-2027 (USD Billion)
88 United Therapeutics Corporation: Products Offered
89 Bayer: Products Offered
90 Gilead Sciences, Inc: Products Offered
91 Johnson & Johnson: Products Offered
92 Viatris Inc.: Products Offered
93 GlaxoSmithKline: Products Offered
94 Sandoz Inc. (Novartis): Products Offered
95 Lupin Pharmaceuticals, Inc: Products Offered
96 Sun Pharmaceutical Industries, Inc.: Products Offered
97 Other Companies: Products Offered
List of Figures
1. Global Pulmonary Arterial Hypertension Market Segmentation & Research Scope
2. Primary Research Partners and Local Informers
3. Primary Research Process
4. Primary Research Approaches
5. Primary Research Responses
6. Global Pulmonary Arterial Hypertension Market: Penetration & Growth Prospect Mapping
7. Global Pulmonary Arterial Hypertension Market: Value ChainAnalysis
8. Global Pulmonary Arterial Hypertension Market Drivers
9. Global Pulmonary Arterial Hypertension Market Restraints
10. Global Pulmonary Arterial Hypertension Market Opportunities
11. Global Pulmonary Arterial Hypertension Market Challenges
12. Key Pulmonary Arterial Hypertension Market Manufacturer Analysis
13. Global Pulmonary Arterial Hypertension Market: Porter’s Five Forces Analysis
14. PESTLE Analysis & Impact Analysis
15. United Therapeutics Corporation: Company Snapshot
16. United Therapeutics Corporation: Swot Analysis
17. Bayer: Company Snapshot
18. Bayer: Swot Analysis
19. Gilead Sciences, Inc: Company Snapshot
20. Gilead Sciences, Inc: Swot Analysis
21. Johnson & Johnson: Company Snapshot
22. Johnson & Johnson: Swot Analysis
23. Viatris Inc.: Company Snapshot
24. Viatris Inc.: Swot Analysis
25. GlaxoSmithKline: Company Snapshot
26. GlaxoSmithKline: Swot Analysis
27. Sandoz Inc. (Novartis): Company Snapshot
28. Sandoz Inc. (Novartis): Swot Analysis
29. Lupin Pharmaceuticals, Inc: Company Snapshot
30. Lupin Pharmaceuticals, Inc: Swot Analysis
31. Sun Pharmaceutical Industries, Inc.: Company Snapshot
32. Sun Pharmaceutical Industries, Inc.: Swot Analysis
33. Other Companies: Company Snapshot
34. Other Companies: Swot Analysis
The Global Pulmonary Arterial Hypertension Market has been studied from the year 2019 till 2027. However, the CAGR provided in the report is from the year 2022 to 2027. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.
The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the Pulmonary Arterial Hypertension Market.
The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.
Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.
Frequently Asked Questions
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
Or view our licence options:
Tailor made solutions just for you
80% of our clients seek made-to-order reports. How do you want us to tailor yours?
OUR CLIENTS
